 （Zhou Haibing）博士，珞珈特聘教授、博士生导师、药学院副院长、化学药物研究所所长。新世纪优秀人才、湖北省首届医学领军人才、学术带头人。从事抗肿瘤(乳腺癌) 和抗病毒药物的设计、合成与开发，具有潜在生物活性的杂环及手性化合物的合成及方法学研究。长期从事雌激素受体（ER）的细胞特异性分子机制，和结构新颖、具有雌激素受体（ER）细胞特异信号调控功能的小分子及药物先导结构的设计和优化研究。已发表SCI论文60余篇，多篇论文发表在,    C,., .,  ., , 等国际著名期刊上。其中以第一作者或通讯作者身份在药物化学顶尖期刊.上发表论文8篇。主持国家自然科学基金重大研究计划培育项目及面上项目、新世纪优秀人才支持计划项目、教育部科学技术研究重大项目、教育部博士点博导类基金等项目10余项。
2000年毕业于化学系有机化学专业，获理学博士学位，导师谢如刚教授。2000年至2001年(The University of Hong Kong, with Prof. Chi-Ming Che)化学系研究助理。2001年至2003年加拿大（University of Ottawa, with Prof. Howard Alper)化学系博士后。2003年至2007年美国香槟分校(University of Illinois at Urbana-Champaign, with Prof. John A. Katzenellenbogen)化学系博士后研究员。2007年至今任武汉大学药学院教授、博士生导师。教学课题：主持2010年武汉大学研究生全英文课程——“高等有机化学”建设项目。教学情况：本科生：药物化学研究生：高等有机化学博士生：药物化学进展社会兼职：药物化学专业委员会委员；湖北省药学会常务理事，药物化学专业委员会主任委员；《》、《》杂志编委；“J Med Chem”、 “Tetrahedron”、“Tetrahedron Letters”、“J Heterocycle Chem”、“Curr topics in med chem”和“Bioorg. Med. Chem. Lett.” 等国际学术期刊审稿人。
研究领域：、有机化学研究兴趣与方向：1) 基于靶点（雌激素受体、HIV逆转录酶等）及结构生物学的新药设计与开发。2) 新型选择性雌激素受体调节剂 (SERMs)、雌激素受体共激活因子结合抑制剂（CBIs）以及抗病毒药物及前体药物的设计、合成与开发；用于乳腺癌早期诊断(PET及纳米技术等)的新型分子显影剂的设计、合成。3) 具有潜在生物活性的杂环化合物的新法合成及活性研究。4) 不对称催化及高选择性有机合成在手性药物及中间体合成中的应用。
承担课题：主持重大研究计划培育项目及面上项目、教育部新世纪优秀人才支持计划项目、教育部博士点博导类基金、教育部留学回国人员科研启动基金等项目多项。1) 主持国家自然科学基金面上项目(No. 81573279), 2016.01.01-2019.12.31。2) 主持国家自然科学基金面上项目(No. 81373255), 2014.01-2017.12。3) 主持湖北省医学领军人才培养工程项目, 2014/01--2016/12。4) 主持武汉市创新人才开发资金资助计划项目, 2014.01-2015.12。5) 主持中央高校基本科研业务费专项资金拔尖创新人才资助项目(No.2042014kf0204), 2014.1 -2015.12, 已结题。6) 主持教育部科学技术研究重大项目(No. 313040), 2013.1-2015.12。7) 主持国家自然科学基金面上项目(No. 81172935), 2012.1-2015.12, 已结题。8) 主持国家自然科学基金重大研究计划培育项目(No. 91017005), 2011.1-2013.12, 已结题。9) 主持武汉市高新技术产业科技创新团队计划项目(2013070204020048), 2013.1-2014.12，已结题。10) 主持教育部新世纪优秀人才支持计划项目(No. NCET-10-0625), 2010.1-2012.12, 已结题。11) 主持国家自然科学基金面上项目(No. 20872116), 2009.1-2011.12, 已结题。12) 主持高等学校博士点基金 (No. 20100141110021), 2011-2013, 已结题。13) 国家科技部重大新药创制专项“武汉综合性新药研究开发技术大平台”(No. 2009ZX09301-014-1, 参加者), 已结题。14) 主持教育部留学回国人员科研启动基金(No.教外司留[2009]1001), 已结题。
指导国家级大学生创新创业训练项目：1) 2009年度：新型选择性雌激素受体调节剂（SERMS）的设计合成及生物活性研究（已结题并评为优秀）。2) 2010年度：具有特殊结构的新型雌激素受体配体的设计合成及生物活性研究。3) 2011年度：新型选择性雌激素受体下调剂（SERDs）的设计合成及生物活性研究。4) 2012年度：新型兼具抗乳腺癌活性和抗炎活性雌激素受体调节剂的设计、合成及其生物活性研究。5) 2013年度：基于双靶点的新型抗肿瘤药物的设计、合成及生物活性研究（已结题并评为优秀）。6) 2014年度：新型吲哚类衍生物的不对称合成及其抗HIV生物活性研究（已结题并评为优秀）（获第七届全国大学生药苑论坛优秀项目三等奖）。7) 2016年度：新型含硒类选择性雌激素受体调节剂（SERMs）的设计、合成及生物活性研究（梁家恩，张斌，倪智豪）。
从事抗肿瘤、抗病毒药物的设计、合成与开发；用于肿瘤早期诊断的新型分子显影剂的设计、合成；具有潜在生物活性的的合成及方法学研究；新型手性配体及催化剂的合成及其不对称催化反应研究等。国际国内学术会议及报告1) Hai-Bing Zhou, Characterization of new selective estrogen receptor downregulators (SERDs) for estrogen-sensitive and tamoxifen-resistant breast cancer. The 10th International Symposium for Chinese Medicinal Chemists (ISCMC). January 18-24, 2016, Taiwan.
2) Chu Tang, Changhao Li, Silong Zhang, Zhiye Hu, Jun Wu, Chune Dong, Jian Huang, and Hai-Bing Zhou*, Novel Bioactive Conjugate Agents Targeting Both Estrogen Receptor and Histone Deacetylase for Treatment of Breast Cancer. 2015 International Chemical Congress of the Pacific Basin Societies (PacifiChem 2015). December 15-20, 2015, Ho Honolulu, Hawaii, USA.3) Hai-Bing Zhou, Diversity-Oriented Synthesis of Novel Ligands to Improving Therapeutics that Target the Estrogen Receptor, 2015年全国药物化学学术会议暨第五届中英药物化学学术会议. 2015, 8月23-26, 中国兰州.4) Hai-Bing Zhou, Novel Selective Estrogen Receptor Modulators (SERMs) of Unusual Structure and Activity: Exploring New Dimensions for Modulating Estrogen Pharmacology. Ninth International Symposium for Chinese Medicinal Chemists (ISCMC-9). August 17-20, 2014, Shenyang, China.5) Hai-Bing Zhou, Novel Selective Estrogen Receptor Modulators (SERMs): Protein-Ligand Interactions and the Dual Regulation Mechanism Study. The 10th SINO-US Chemistry Professors Conference. June 15-17, 2014, Jinan, China.6) Hai-Bing Zhou, Progress on selective estrogen receptor modulators with novel scaffolds and dual regulation activities. 第八届全国有机化学学术会议. 2013年10月17-20, 重庆.7) 雌激素受体的小分子双重调控及相关药物研究. 2013年全国药物化学学术会议暨第四届中英药物化学学术会议. 2013年11月1-3, 济南.8) Hai-Bing Zhou, Progress in discovery of new selective estrogen receptor modulators (SERMs) based on novel structural templates. The 9th SINO-US Chemistry Professors Conference. July 12-14, 2013, Chengdu, China.9) Hai-Bing Zhou, Novel bivalent ligands for the estrogen receptor: Design, synthesis and biological study. The 21èmes Conférences Européennes du Groupement des Pharmacochimistes de lArc Atlantique (GP2A) et 27èmes journées Franco-Belges de Pharmacochimie. June 5-7, 2013, Lille, France.10) Hai-Bing Zhou, Study on the dual regulation of estrogen receptor with small molecules. “Ninth IUPAC International Symposium on Biomolecular Chemistry & Eighth International Symposium for Chinese Medicinal Chemists (ISCMC-8)“. August 25-29, 2012, Beijing China.11) Hai-Bing Zhou, Novel Bifunctional Ligands for Dual Regulation of Estrogen Receptor. The 8th SINO-US Chemistry Professors Conference. July 1-4, 2012, Kunming, China.12) Hai-Bing Zhou, Novel Selective Estrogen Receptor Modulators (SERMs) Based on a Diversity-Oriented Synthesis. 2011年全国药物化学学术会议. 2011年11月17-20, 广州.13) Jian Min, Pengcheng Wang, Chune Dong and Hai-Bing Zhou*. Design, Synthesis and Biological Evaluation of a Novel Series of Thiophenes: Ligands Selective for Estrogen Receptor β. 第七届全国有机化学学术会议, 2011年11月12-15, 南京.14) Hai-Bing Zhou, Diversity-Oriented Synthesis Leads to an Effective Class of Novel Selective Estrogen Receptor Modulators (SERMs). The 7th SINO-US Chemistry Professors Conference, June 27-30, 2011, Guiyang, China15) Hai-Bing Zhou, Yangfan Zheng, Pengcheng Wang, John A. Katzenellenbogen, Kendall W. Nettles, Modular synthesis and biological evaluation of novel estrogen receptor ligands based on a 7-thia-bicyclo[2.2.1]hept-2-ene-7-oxide or 7-oxabicyclo[2.2.1]hept-5-ene skeleton. 242nd ACS National Meeting. August 28−September 1, 2011 in Denver, Colorado.16) Hai-Bing Zhou. Discovery and structure-based design of novel selective estrogen receptor modulators (SERMs). 中国化学会 全国第三届有机合成化学与过程学术讨论会，重庆，2010,10月18-21日.17) Pengcheng Wang, Yangfan Zheng, Manghong Zhu, Liyan Ma, Jian Min, Chune Dong and Hai-Bing Zhou*. Synthesis and Biological Evaluation of Novel Estrogen Receptor Ligands with Bridged bicyclic Core Structures. The 7th International Symposium for Chinese Medicinal Chemists (ISCMC). February 1 to February 5, 2010, Taiwan.
论著及教材：1) Yuzhi Lu, Ze Dong, Pengcheng Wang, and Hai-Bing Zhou*, Thiophene Oxidation and Reduction Chemistry. Topics in Heterocyclic Chemistry: Thiophenes. Chapter 6. Editors, John A. Joule, Springer International Publishing. 2015, Volume 39. Pages 227-293. DOI: 10.1007/978-3-319-07824-3.2) 《现代制药工艺学》（全国工程硕士专业学位教育指导委员会推荐教材）（参编）。第八章，固相化学合成制药；第九章，化学药物合成的新方法。赵广荣主编，清华大学出版社出版，2015，Pages 203-303。ISBN 978-7-302-38423-6.3) 《药物化学》(普通高等教育“十一五”国家级规划教材，第三版，参编)，第十六章，甾体激素药物；第十九章，抗病毒药。尤启冬主编，化学工业出版社，2015，Pages 366-391；Pages 463-486。ISBN 978-7-122-24850-3.4) 《药物设计学》(全国普通高等医学院校药学类专业“十三五”规划教材，副主编)，第三章，先导化合物发现的基本方法，2016，Pages 45-71。ISBN 978-7-5067-7885-5。
代表性论文：已在国外期刊上发表SCI论文40多篇，多篇论文发表在Nature Chemical Biology, Chemistry Biology J. Med. Chem., J. Org. Chem., Bioconjugate Chem., Chem. Comm., Chem.-Eur. J., Bioorg. Med. Chem. Lett.等国际著名期刊上。
1) Full Antagonism of the Estrogen Receptor without a Prototypical Ligand Side Chain. Sathish Srinivasan, Jerome C. Nwachukwu, Nelson E. Bruno, Venkatasubramanian Dharmarajan, Devrishi Goswami, Irida Kastrati, Scott Novick, Jason Nowak, Valerie Cavett, Hai-Bing Zhou, Nittaya Boonmuen, Yuechao Zhao, Jian Min,Jonna Frasor, Be, nita S. Katzenellenbogen, Patrick R. Griffin, John A. Katzenellenbogen, Kendall W. Nettles*.  2016, AOP, doi:10.1038/nchembio.2236. (IF: 12.709)2) Gossypol with Hydrophobic Linear Esters Exhibits Enhanced Anti-Tumor Activity as an Inhibitor of Antiapoptotic Proteins. Yuzhi Lu, Shuangchan Wu, Yuan Yue, Si He, Jun Li, Jun Tang, Wei Wang,* and Hai-Bing Zhou*. , 2016, Article ASAP. (IF: 3.355)3) Identification and Structure–Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors. Xin Han, Ningyuan Sun, Haoming Wu, Deyin Guo, Po Tien, Chune Dong, Shuwen Wu*, and Hai-Bing Zhou*. . 2016,  (5), 2139-2150. (IF: 5.589) (Highlighted by BioCentury Innovations (Formerly SciBX, Science-Business eXchange) on March 3, 2016)4) Predictive Features of Ligand-Specific Signaling through the Estrogen Receptor. Jerome C. Nwachukwu, Sathish Srinivasan, Yangfan Zheng, Song Wang, Jian Min, Chune Dong, Zongquan Liao, Jason Nowak, Nicholas J. Wright, René Houtman, Kathryn E. Carlson, Jatinder S. Josan, Olivier Elemento, John A. Katzenellenbogen*, Hai-Bing Zhou*, Kendall W. Nettles*.  2016, , 864. (IF: 10.581)5) Application of chiral squaramides:from asymmetric organocatalysis to biologically active compounds. Xin Han, Hai-Bing Zhou, Chune Dong*.  2016,  (2), 897-906. (IF: 3.459)6) Synthesis and structure–activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy. Changhao Li, Chu Tang, Zhiye Hu, Chenxi Zhao, Chenlu Li, Silong Zhang, Chune Dong, Hai-Bing Zhou*, Jian Huang*,  2016,  (13), 3062-3074. (IF: 2.923)7) Sarah Preston, Junjie Luo, Yuezhou Zhang, Abdul Jabbar, Simon Crawford, Jonathan Baell, Andreas Hofmann, Min Hu, Hai-Bing Zhou* and Robin B. Gasser*. Selenophene and thiophene-core estrogen receptor ligands that inhibit motility and development of parasitic stages of Haemonchus contortus.  2016,, 346. (IF: 3.234)8) Novel Bioactive Hybrid Compounds Dual Targeting Estrogen Receptor and Histone Deacetylase for Treatment of Breast Cancer. Chu Tang, Changhao Li, Silong Zhang, Zhiye Hu, Jun Wu, Chune Dong*, Jian Huang*, and Hai-Bing Zhou*. . 2015,  (11), 4550-4572. (IF: 5.447)9) Tunable Bifunctional Phosphine Squaramide Promoted Morita-Baylis-Hillman Reaction of N-alkyl Isatins with Acrylates. Ze Dong, Chao Yan, Yongzhi Gao, Chune Dong, Guofu Qiu*, Hai-Bing Zhou*. . 2015,  (9), 2132–2142. (IF: 5.663).10) Synthesis of N-benzyl-N-phenylthiophene-2-carboxamide Analogues as a Novel Class of Enterovirus 71 Inhibitors. Jiawei Pan, Xin Han, Ningyuan Sun, Haoming Wu, Dandan Lin, Po Tien, Hai-Bing Zhou* and Shuwen Wu*.  2015,  (31), 55100-55108. (IF: 3.840)11) Recyclable BINOL-Quinine-Squaramide as Highly Efficient Organocatalyst for α-Amination of 1, 3-Dicarbonyl Compounds and α-Cyanoacetates. Yongzhi Gao, Bin Liu, Wei Wang, Hai-Bing Zhou and Chune Dong*.  2015,  (31), 24392-24396. (IF: 3.840)12) Halolactones are Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. X. Han, H. Wu, C. Dong, P. Tien, W. Xie, S. W. Wu*, H.-B. Zhou*.  2015,  (13), 10005-10013. (IF: 3.840)13) Triaryl-substituted Schiff Bases are High-Affinity Subtype-Selective Ligands for the Estrogen Receptor. Zong-Quan Liao, Chune Dong, Kathryn E. Carlson, Sathish Srinivasan, Jerome C. Nwachukwu, Robert W. Chesnut, Abhishek Sharma, Kendall W. Nettles, John A. Katzenellenbogen,* and Hai-Bing Zhou*. . 2014,  (8), 3532-3545. (IF: 5.447)14) C3-Symmetric Cinchonine-Squaramide-Catalyzed Asymmetric Chlorolactonization of Styrene-Type Carboxylic Acids with 1,3-Dichloro-5,5-dimethylhydantoin: An Efficient Method to Chiral Isochroman-1-ones. Xin Han, Chune Dong, and Hai-Bing Zhou*. . 2014,  (6), 1275–1280. (IF: 5.663).15) Synthesis and SARs of Indole-based α-Amino Acids as Potent HIV-1 Non-Nucleoside Reversed Transcriptase Inhibitors. Xin Han, Haoming Wu, Wei Wang, Chune Dong, Po Tien, Shuwen Wu*, Hai-Bing Zhou*. ., 2014,  (41), 8308 - 8317. (IF: 3.562)16) One-pot to fused pyrazoles by a double cyclization of o-alkynylaldehydes with ketones and hydrazine under metal-free condition, Jinxia Qiao, Bin Liu, Zongquan Liao, Ying Li, Lei Ma, Chune Dong, and Hai-Bing Zhou*.  2014,  (24), 3782-3787. (IF: 2.641)17) Thiophene-Core Estrogen Receptor Ligands Having Superagonist Activity. Jian Min, Pengcheng Wang, Sathish Srinivasan, Jerome C. Nwachukwu, Pu Guo, Minjian Huang, Kathryn E. Carlson, John A. Katzenellenbogen*, Kendall W. Nettles, Hai-Bing Zhou*. ., 2013,  (8), 3346–3366. (IF: 5.480)18) Enantioselective inhibition of reverse transcriptase (RT) of HIV-1 by non-racemic indole-based trifluoropropanoates developed by asymmetric catalysis using recyclable organocatalysts. Xin Han, Wenjie Ouyang, Bin Liu, Wei Wang*, Po Tien, Shuwen Wu*, Hai-Bing Zhou*. ., 2013, 11 (48), 8463-8475. (IF: 3.487)19) Highly enantioselective Michael addition of 1, 3-dicarbonyl compounds to nitroalkenes catalyzed by designer chiral BINOL-Quinine-Squaramide: Efficient access to optical active nitroalkanes and their isoxazole derivatives. Bin Liu, Xin Han, Ze Dong, Hao Lv, Hai-Bing Zhou, Chune Dong*.  2013,  (20), 1276-1280. (IF: 2.165)20) Design, Synthesis and Biological Evaluation of Novel Estrogen-derived Steroidal Metal Complexes. Xinlong Zhang, Ziqing Zuo, Juan Tang, Kai Wang, Caihua Wang, Weiyan Chen, Changhao Li, Wen Xu, Xiaolin Xiong, Kangxiang Yuntai, Jian Huang, Xiaoli Lan, Hai-Bing Zhou*. . 2013,  (13), 3793-3797. (IF: 2.331)21) Modification of peptides and proteins via HMDO-mediated ligation in ionic liquids. Jianli Duan, Yao Sun, Hao Chen, Guofu Qiu, Haibing Zhou, Ting Tang, Zixin Deng, Xuechuan Hong*. . 2013,  (14), 7013–7022. (IF: 4.638)22) Identification and Structure-Activity Relationships of a Novel Series of Estrogen Receptor Ligands Based on 7-Thiabicyclo[2.2.1]hept-2-ene-7-oxide. Pengcheng Wang, Jian Min, Jerome C. Nwachukwu, Valerie Cavett, Kathryn E. Carlson, Pu Guo, Manghong Zhu, Yangfan Zheng, Chune Dong, John A. Katzenellenbogen*, Kendall W. Nettles, Hai-Bing Zhou*. . 2012,  (5), 2324-2341. (IF: 5.614)23) An Expedient Approach to Highly Enantioenriched Cyclic Nitrones Mediated by Robust and Recoverable C3-Symmetric Cinchonine-Squaramide Catalysts. Xin Han, Xiangfei Wu, Chang Min, Hai-Bing Zhou, Chune Dong*.  2012, (19), 7501-7505.24) Synthesis, biological evaluation and structure activity relationships of new estrogen receptor ligands based on a bridged oxabicyclic core embellished with arylsulfonamides. Manghong Zhu, Chen Zhang, Jerome C. Nwachukwu, Sathish Srinivasan, Valerie Cavett, Yangfan Zheng, Kathryn E. Carlson, Chune Dong, John A. Katzenellenbogen*, Kendall W. Nettles, Hai-Bing Zhou*. ., 2012,  (43), 8692-8700. (IF: 3.568)25) Discovery of novel SERMs with a ferrocenyl entity based on the oxabicyclo[2.2.1]heptene scaffold and evaluation of their antiproliferative effects in breast cancer cells. Yangfan Zheng, Caihua Wang, Changhao Li, Jinxia Qiao, Feng Zhang, Minjian Huang, Wenming Ren, Chune Dong, Jian Huang*, Hai-Bing Zhou*. ., 2012,  (48), 9689-9699. (IF: 3.568)26) Development of Selective Estrogen Receptor Modulator (SERM)-Like Activity Through an Indirect Mechanism of Estrogen Receptor Antagonism: Defining the Binding Mode of 7-Oxabicyclo[2.2.1]hept-5-ene Scaffold Core Ligands. Yangfan Zheng, Manghong Zhu, Sathish Srinivasan, Jerome C. Nwachukwu, Valerie Cavett, Jian Min, Kathryn E. Carlson, Pengcheng Wang, Chune Dong, John A. Katzenellenbogen*, Kendall W. Nettles, Hai-Bing Zhou*.  2012,  (6), 1094-1100. (IF: 2.835)27) Enhanced efficiency of recyclable C3-symmetric cinchonine-squaramides in the asymmetric Friedel–Crafts reaction of indoles with alkyl trifluoropyruvate. Xin Han, Bin Liu, Hai-Bing Zhou, Chune Dong*.  2012,  (18-19), 1332-1337. (IF: 2.115)28) Chiral Squaramide as Multiple H-Bonds Donor Organocatalyst for Asymmetric Michael addition of 1, 3-Dicarbonyl Compounds to Nitroolefins. Ze Dong, Guofu Qiu, Hai-Bing Zhou, Chune Dong*.  2012,  (22-23), 1550-1556. (IF: 2.115)29) A simple and straightforward approach toward selective C=C bond reduction by hydrazine. Hao Chen, Jianmin Wang, Xuechuan Hong, Hai-Bing Zhou, Chune Dong*. . 2012,  (9), 758-761. (IF: 0.964).30) C3-Symmetric Cinchonine-Squaramide as New Highly Efficient, and Recyclable Organocatalyst for Enantioselective Michael Addition. Chang Min, Xin Han, Zongquan Liao, Xiangfei Wu, Hai-Bing Zhou, Chune Dong*. . 2011,  (14-15), 2715–2720. (IF: 6.048).31) Metal-free Direct Amidation of Peptidyl Thiol Esters with α-Amino Esters. Hao Chen, Maomao He, Yaya Wang, Linhui Zhai, Yongbo Cui, Yangyan Li, Yan Li, Haibing Zhou*, Xuechuan Hong* and Zixin Deng. . 2011, , 2723-2726. (IF: 6.320)32) A Novel C3-Symmetric Prolinol-Squaramide Catalyst for the Asymmetric Reduction of Ketones by Borane. Xiang-Fei Wu, Chang Min, Hai-Bing Zhou, Chune Dong*.  2011,  (16-17), 1640–1643. (IF: 2.652)33) Highly diastereoselective synthesis of quaternary α-trifluoromethyl α-amino acids from chiral imines of trifluoropyruvate, Qiao-Qiao Min, Chun-Yang He, Haibing Zhou and Xingang Zhang, . 2010, , 8029-8031. (IF: 5.787)34) Imaging progesterone receptor in breast tumors: Synthesis and receptor binding affinity of fluoroalkyl-substituted analogs of Tanaproget. Hai-Bing Zhou, Jae Hak Lee, Christopher G. Mayne, Kathryn E. Carlson, John A. Katzenellenbogen*,. 2010,  (8), 3349–3360. (IF: 5.207)35) Development of [F-18]Fluorine-Substituted Tanaproget as a Progesterone Receptor Imaging Agent for Positron Emission Tomography. Jae Hak Lee, Hai-Bing Zhou, Carmen S. Dence, Kathryn E. Carlson, Michael J. Welch, John A. Katzenellenbogen*, . 2010,  (6), 1096-1104. (IF: 5.002)36) Analogs of methyl-piperidinopyrazole (MPP): Antiestrogens with estrogen receptorselective activity. Hai-Bing Zhou, Kathryn E. Carlson, Fabio Stossi, Benita S. Katzenellenbogen, John A. Katzenellenbogen*. . 2009,  (1), 108-110. (IF: 2.650)37) Bromination from the Macroscopic Level to the Tracer Radiochemical Level: 76Br Radiolabeling of Aromatic Compounds via Electrophilic Substitution. Dong Zhou, Haibing Zhou, Carl C. Jenks, Jason S. Lewis, John A. Katzenellenbogen, and Michael J. Welch*. . 2009,  (4) 808-816. (IF: 4.350)38) Fluorine-18 labeling and biodistribution studies on peroxisome proliferator-activated receptor-γ ligands: potential positron emission tomography imaging agents. Byung Chul Lee, Carmen S. Dence, Haibing Zhou, Ephraim E. Parent, Michael J. Welch, John A. Katzenellenbogen*. . 2009,  (2) 147-153. (IF: 2.456)39) NFkB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. K. W. Nettles*, J. B. Bruning, G. Gil, J. Nowak, S. K. Sharma, J. B. Hahm, K. Kulp, R. B. Hochberg, H. B. Zhou, J. A. Katzenellenbogen, B. S. Katzenellenbogen, Y. Kim, A. Joachmiak, G. G. Greene,  2008,  (4), 241-247. (IF: 14.612)40) Elemental Isomerism: A Boron-Nitrogen Surrogate for a Carbon-Carbon Double Bond Increases the Chemical Diversity of Estrogen Receptor Ligands. Hai-Bing Zhou, Kendall W. Nettles, John B. Bruning, Younchang Kim, Andrzej Joachimiak, Sanjay Sharma, Kathryn E. Carlson, Fabio Stossi, Benita S. Katzenellenbogen, Geoffrey L. Greene and John A. Katzenellenbogen*,  2007,  (6), 659-669. (IF: 5.718)41) Bicyclo[2.2.2]octanes: Close Structural Mimics of the Nuclear Receptor-binding Motif of Steroid Receptor Coactivators. Hai-Bing Zhou, Margaret L. Collins, Jillian R. Gunther, John S. Comninos and John A. Katzenellenbogen*, . 2007,  (15), 4118-4122. (IF: 2.604)42) Structure-Guided Optimization of Estrogen Receptor Binding Affinity and Antagonist Potency of Pyrazolopyrimidines with Basic Side Chain. Hai-Bing Zhou, Shubin Sheng, Dennis R. Compton, Younchang Kim, Andrzej Joachimiak, Sanjay Sharma, Kathryn E. Carlson, B. S. Katzenellenbogen, Kendall W. Nettles, Geoffrey L. Greene and John A. Katzenellenbogen*, . 2007,  (2), 399-403. (IF: 4.895)43) Synthesis and Evaluation of Estrogen Receptor Ligands with Bridged Oxabicyclic Cores Containing a Diarylethylene Motif: Estrogen Antagonists of Unusual Structure. Hai-Bing Zhou, John S. Comninos, Fabio Stossi, Benita S. Katzenellenbogen, and John A. Katzenellenbogen*, . 2005,  (23), 7261-7274.
授权专利：1) 周海兵，陈浩，王健民，董春娥，一种水合肼微波还原碳碳双键的方法。申请日期，2010-10-25。授权日期，2013-04-03，中国专利号，ZL 201010518663.4。2) 洪学传，邓子新，周海兵，陈浩等，一种酰胺类化合物的合成方法。申请日期，2011.1.13。授权日期，2013-04-24，中国专利号，ZL 201110006690.8。3) 吴叔文，周海兵，田波，董春娥，欧阳文杰，韩欣，一种吲哚类化合物及其作为HIV-1逆转录酶抑制剂的应用。申请日期，2013.3.11。授权日期，2015-04-7，中国专利号，201310076738.1。4) 董春娥，刘斌，乔金霞，周海兵，一种制备吡唑异吲哚类化合物的方法。申请日期，2013.6.9. 授权日期，2015-05-6，中国专利号，201310228096.2.5) 周海兵，吴叔文，田波，舒红兵，韩欣，吴浩明，一种苯并内酯类化合物及其在制备抗艾滋病药物中的应用。申请日期，2014.5.23。申请号：201410220019.7。授权日期，2016.2.15。中国专利号：ZL201410220019.7。6) 周海兵，吴叔文，田波，董春娥，欧阳文杰，韩欣，一种吲哚-α-氨基酸类化合物及其在制备抗艾滋病药物中的应用。申请日期，2014.5.22。申请号：201410218599.6。授权日期，2016.1.27。中国专利号：ZL 201410218599.6。7) 周海兵，黄健，唐初，李长浩，董春娥，张思龙，一种氧桥双环-[2.2.1]-庚烯类化合物及其用途。申请日期，2014.9.25。申请号：201410493223.6。授权日期，2016-04-6，中国专利号，201410493223.6。8) 王巍，吴叔文，何思，黄靖，周海兵，舒红兵，田波，作为甲型流感病毒抑制剂的甲酰胺和异腈类化合物及其制备与应用。申请日期，2014.04.14。授权日期，2014-07-16，中国专利号，ZL201410147716.4。9) 周海兵，吴叔文，韩欣，田波，舒红兵，吴浩明，一种酰肼类化合物及其在制备抗手足口病药物中的应用。申请日期，2015.4.24。申请号：201510196726.1。授权日期，2016-07-20，中国专利号，ZL201510196726.1。
1) 2016年湖北省自然科学奖三等奖2） 2013年湖北省首届医学领军人才3) 2012年武汉大学珞珈学者特聘教授4) 2010年生命化学研究奖5) 2009年教育部新世纪优秀人才
武汉大学教育部病毒学国家重点实验室教育部 四川大学香港大学渥太华大学伊利诺伊大学中国药学会中国药物化学杂志现代药物与临床 药物化学 国家自然科学基金  杂环化合物   ,   药明康德 